R Fleischmann

Summary

Affiliation: The University of Texas Southwestern Medical Center at Dallas
Country: USA

Publications

  1. doi request reprint Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs
    Roy Fleischmann
    Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX 75231, USA
    Arthritis Rheum 64:617-29. 2012
  2. doi request reprint Tocilizumab inhibits structural joint damage and improves physical function in patients with rheumatoid arthritis and inadequate responses to methotrexate: LITHE study 2-year results
    Roy M Fleischmann
    Metroplex Clinic Research Center, Dallas, Texas, USA Panorama Medical Center, Cape Town, South Africa
    J Rheumatol 40:113-26. 2013
  3. doi request reprint Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis
    Roy Fleischmann
    Metroplex Clinical Research Center, Dallas, TX 75231, USA
    N Engl J Med 367:495-507. 2012
  4. doi request reprint Novel small-molecular therapeutics for rheumatoid arthritis
    Roy Fleischmann
    University of Texas Southwestern Medical Center, Dallas, Texas, USA
    Curr Opin Rheumatol 24:335-41. 2012
  5. ncbi request reprint Primer: establishing a clinical trial unit - regulations and infrastructure
    Roy Fleischmann
    University of Texas Southwestern Medical Center at Dallas, and Metroplex Clinical Research Center, Dallas, TX 75235, USA
    Nat Clin Pract Rheumatol 3:234-9. 2007
  6. ncbi request reprint Primer: establishing a clinical trial unit--obtaining studies and patients
    Roy Fleischmann
    University of Texas Southwestern Medical Center, Dallas, TX, USA
    Nat Clin Pract Rheumatol 3:459-63. 2007
  7. pmc Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: a randomised controlled trial in patients with osteoarthritis
    Roy Fleischmann
    The University of Texas Southwestern Medical Center at Dallas, MCRC, Dallas, Texas, USA
    BMC Musculoskelet Disord 9:32. 2008
  8. doi request reprint Safety of biologic therapy in rheumatoid arthritis and other autoimmune diseases: focus on rituximab
    Roy M Fleischmann
    University of Texas Southwestern Medical Center, and Metroplex Clinical Research Center, Dallas, TX 75235 5360, USA
    Semin Arthritis Rheum 38:265-80. 2009
  9. pmc Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study
    R Fleischmann
    University of Texas Southwestern Medical Center, Dallas, 75235, USA
    Ann Rheum Dis 68:805-11. 2009
  10. doi request reprint Progressive multifocal leukoencephalopathy following rituximab treatment in a patient with rheumatoid arthritis
    R M Fleischmann
    Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX 75231, USA
    Arthritis Rheum 60:3225-8. 2009

Detail Information

Publications34

  1. doi request reprint Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs
    Roy Fleischmann
    Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX 75231, USA
    Arthritis Rheum 64:617-29. 2012
    ....
  2. doi request reprint Tocilizumab inhibits structural joint damage and improves physical function in patients with rheumatoid arthritis and inadequate responses to methotrexate: LITHE study 2-year results
    Roy M Fleischmann
    Metroplex Clinic Research Center, Dallas, Texas, USA Panorama Medical Center, Cape Town, South Africa
    J Rheumatol 40:113-26. 2013
    ....
  3. doi request reprint Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis
    Roy Fleischmann
    Metroplex Clinical Research Center, Dallas, TX 75231, USA
    N Engl J Med 367:495-507. 2012
    ..Tofacitinib (CP-690,550) is a novel oral Janus kinase inhibitor that is being investigated as a targeted immunomodulator and disease-modifying therapy for rheumatoid arthritis...
  4. doi request reprint Novel small-molecular therapeutics for rheumatoid arthritis
    Roy Fleischmann
    University of Texas Southwestern Medical Center, Dallas, Texas, USA
    Curr Opin Rheumatol 24:335-41. 2012
    ..This article reviews the progress made in the development of these compounds over the past year...
  5. ncbi request reprint Primer: establishing a clinical trial unit - regulations and infrastructure
    Roy Fleischmann
    University of Texas Southwestern Medical Center at Dallas, and Metroplex Clinical Research Center, Dallas, TX 75235, USA
    Nat Clin Pract Rheumatol 3:234-9. 2007
    ..The purpose of this article is to review these requirements in depth, as well as to discuss the infrastructure required to establish a successful clinical trial unit...
  6. ncbi request reprint Primer: establishing a clinical trial unit--obtaining studies and patients
    Roy Fleischmann
    University of Texas Southwestern Medical Center, Dallas, TX, USA
    Nat Clin Pract Rheumatol 3:459-63. 2007
    ..If done properly, however, clinical investigation can be rewarding--both intellectually and financially...
  7. pmc Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: a randomised controlled trial in patients with osteoarthritis
    Roy Fleischmann
    The University of Texas Southwestern Medical Center at Dallas, MCRC, Dallas, Texas, USA
    BMC Musculoskelet Disord 9:32. 2008
    ..d.) and 100 mg twice daily (b.i.d.) with those of celecoxib 200 mg o.d. on retention on treatment over 1 year...
  8. doi request reprint Safety of biologic therapy in rheumatoid arthritis and other autoimmune diseases: focus on rituximab
    Roy M Fleischmann
    University of Texas Southwestern Medical Center, and Metroplex Clinical Research Center, Dallas, TX 75235 5360, USA
    Semin Arthritis Rheum 38:265-80. 2009
    ..To review the safety of biologic agents used to treat rheumatoid arthritis (RA) and other autoimmune diseases, with a focus on rituximab...
  9. pmc Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study
    R Fleischmann
    University of Texas Southwestern Medical Center, Dallas, 75235, USA
    Ann Rheum Dis 68:805-11. 2009
    ..This study evaluated the efficacy and safety of certolizumab pegol 400 mg, a novel, poly-(ethylene glycol) (PEG)ylated, Fc-free TNFalpha inhibitor, as monotherapy in patients with active RA...
  10. doi request reprint Progressive multifocal leukoencephalopathy following rituximab treatment in a patient with rheumatoid arthritis
    R M Fleischmann
    Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX 75231, USA
    Arthritis Rheum 60:3225-8. 2009
    ....
  11. ncbi request reprint The efficacy and safety of golimumab in the treatment of arthritis
    Roy Fleischmann
    University of Texas Southwestern Medical School, Metroplex Clinical Research Center, 8144 Walnut Hill Lane, Suite 800, Dallas, Texas 75231, USA
    Expert Opin Biol Ther 10:1131-43. 2010
    ..Biologic therapies have dramatically changed the long-term prognosis of patients with rheumatoid and psoriatic arthritis and ankylosing spondylitis...
  12. ncbi request reprint Risk: benefit profile of etanercept in elderly patients with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis
    Roy Fleischmann
    The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75235, USA
    Drugs Aging 24:239-54. 2007
    ..Only by understanding the risks and benefits of therapy in the older age group can a true risk : benefit profile for etanercept, and ultimately other anti-TNFalpha therapies, be determined by the practising physician and the patient...
  13. pmc Long term safety of etanercept in elderly subjects with rheumatic diseases
    R Fleischmann
    University of Texas Southwestern Medical Center at Dallas, 5939 Harry Hines Boulevard, Dallas, Texas 75235, USA
    Ann Rheum Dis 65:379-84. 2006
    ....
  14. ncbi request reprint Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a prospective randomized 13-week study versus placebo and celecoxib
    Roy Fleischmann
    University of Texas Southwestern Medical Center, Radiant Research Dallas, 5939 Harry Hines Boulevard, Dallas, 75235, USA
    Clin Rheumatol 25:42-53. 2006
    ..Lumiracoxib demonstrated a tolerability profile similar to placebo and celecoxib...
  15. ncbi request reprint Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept
    Roy Fleischmann
    Radiant Research Dallas, Dallas, Texas 75235, USA
    Drug Saf 25:173-97. 2002
    ..Preliminary data show that it may be well tolerated and effective in other rheumatic diseases in which there is over production of TNFalpha...
  16. doi request reprint The clinical efficacy and safety of certolizumab pegol in rheumatoid arthritis
    Roy Fleischmann
    Metroplex Clinical Research Center, 8144 Walnut Hill Lane, Dallas, Texas 75231, USA
    Expert Opin Biol Ther 10:773-86. 2010
    ..Another medication, such as certolizumab pegol, is a welcome addition to our treatment armamentarium of rheumatoid arthritis...
  17. ncbi request reprint Safety and efficacy of disease-modifying antirheumatic agents in rheumatoid arthritis and juvenile rheumatoid arthritis
    Roy Fleischmann
    University of Texas Southwestern Medical Center at Dallas, St Paul University Hospital, 5939 Harry Hines Boulevard, Suite 400, Dallas, Texas 75235, USA
    Expert Opin Drug Saf 2:347-65. 2003
    ....
  18. ncbi request reprint Anakinra: an inhibitor of IL-1 for the treatment of rheumatoid arthritis
    Roy Fleischmann
    Radiant Research Dallas, 5939 Harry Hines Boulevard, Suite 400, Dallas, Texas 75235 5360, USA
    Expert Opin Biol Ther 4:1333-44. 2004
    ..Anakinra should not be given in combination with anti-TNF agents...
  19. ncbi request reprint Developing a new generation of TNFalpha antagonists for the treatment of rheumatoid arthritis
    Roy Fleischmann
    University of Texas Southwestern Medical Center, Dallas, TX, USA
    Mol Interv 3:310-8. 2003
  20. ncbi request reprint Meloxicam
    Roy Fleischmann
    University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Boulevard, Dallas, Texas 75390, USA
    Expert Opin Pharmacother 3:1501-12. 2002
    ..Adverse events, including peripheral oedema and hypertension, occurred at a similar rate as with traditional NSAIDs...
  21. pmc Does safety make a difference in selecting the right TNF antagonist?
    Roy Fleischmann
    University of Texas Southwestern Medical Center, Dallas, TX, USA
    Arthritis Res Ther 6:S12-8. 2004
    ..Overall, the anti-TNF agents are well tolerated and have demonstrated a favorable benefit-to-risk profile in patients with RA...
  22. doi request reprint Kinase inhibitors: a new approach to rheumatoid arthritis treatment
    Stanley Cohen
    Metroplex Clinical Research Center, Dallas, Texas, USA
    Curr Opin Rheumatol 22:330-5. 2010
    ..This article will review the recent publications on these efforts...
  23. ncbi request reprint In quest of the Holy Grail: efficacy versus effectiveness in rheumatoid arthritis
    Roy Fleischmann
    J Rheumatol 29:2018-9; author reply 2019. 2002
  24. ncbi request reprint Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial
    John C Davis
    University of California, San Francisco, CA 94143, USA
    Arthritis Rheum 48:3230-6. 2003
    ..To determine the safety and efficacy of etanercept in a multicenter, randomized, placebo-controlled, double-blind trial of adults with moderate to severe active ankylosing spondylitis (AS)...
  25. ncbi request reprint Dose response and safety study of meloxicam up to 22.5 mg daily in rheumatoid arthritis: a 12 week multicenter, double blind, dose response study versus placebo and diclofenac
    Daniel E Furst
    Virginia Mason Research Center Seattle, Washington 98101, USA
    J Rheumatol 29:436-46. 2002
    ..This Phase III, placebo and active controlled, multicenter trial evaluated the efficacy and safety of meloxicam 7.5, 15, and 22.5 mg daily for the treatment of rheumatoid arthritis (RA)...
  26. ncbi request reprint The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial
    Paul Emery
    Academic Unit of Musculoskeletal Disease, Chapel Allerton Hospital, Leeds, UK
    Arthritis Rheum 54:1390-400. 2006
    ....
  27. ncbi request reprint Treatment of osteoarthritis with anakinra
    Imran Iqbal
    Curr Rheumatol Rep 9:31-5. 2007
    ..This article reviews the data on the use of anakinra in OA treatment...
  28. ncbi request reprint The safety of anakinra in high-risk patients with active rheumatoid arthritis: six-month observations of patients with comorbid conditions
    Michael H Schiff
    Denver Arthritis Clinic, Colorado 80230, USA
    Arthritis Rheum 50:1752-60. 2004
    ..To determine in a placebo-controlled, double-blind trial the safety profile of daily anakinra (Kineret) use in patients with active rheumatoid arthritis (RA) and concurrent comorbid conditions...
  29. ncbi request reprint Concomitant medication use in a large, international, multicenter, placebo controlled trial of anakinra, a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis
    John Tesser
    University of Arizona Health Sciences Center, Arizona Rheumatology Center, Phoenix, Arizona 85015 2160, USA
    J Rheumatol 31:649-54. 2004
    ..To examine the safety of anakinra when added to a background of standard rheumatoid arthritis (RA) medications in patients with RA with active disease...
  30. ncbi request reprint Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis
    Edward Keystone
    Mount Sinai Hospital, and University of Toronto, 600 University Avenue, Toronto, Ontario, Canada
    Arthritis Rheum 56:3896-908. 2007
    ..To determine the safety and efficacy of additional courses of rituximab in patients with rheumatoid arthritis (RA)...
  31. pmc Do anti-TNF agents have equal efficacy in patients with rheumatoid arthritis?
    Sergio Schwartzman
    Hospital for Special Surgery, New York, NY, USA
    Arthritis Res Ther 6:S3-S11. 2004
    ..When selecting a TNF antagonist, rheumatologists should weigh evidence and experience with specific agents before a decision is made for use in therapy...
  32. ncbi request reprint Tacrolimus in rheumatoid arthritis
    Roy Fleischmann
    University of Texas Southwestern Medical Centre at Dallas, USA
    Expert Opin Pharmacother 7:91-8. 2006
    ..This article reviews the pharmacodynamics, pharmacokinetics, clinical efficacy, safety and role of tacrolimus in the treatment of rheumatoid arthritis...
  33. ncbi request reprint A phase 2 dose-finding study of PEGylated recombinant methionyl human soluble tumor necrosis factor type I in patients with rheumatoid arthritis
    Daniel E Furst
    Department of Rheumatology, University of California at Los Angeles, California 90095, USA
    J Rheumatol 32:2303-10. 2005
    ..In a phase 2 study, to assess the efficacy and safety of pegsunercept, a soluble tumor necrosis factor receptor type I, for the treatment of rheumatoid arthritis (RA)...
  34. doi request reprint Clinical studies can be performed in an ethical manner
    Roy Fleischmann
    Nat Clin Pract Rheumatol 4:E5; author reply E6. 2008